Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2014 - 20154

Settings

search.filters.applied.f.language: search.filters.language.engSubject: search.filters.subject.adverse effects

Search Results

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Efficacy and Safety of Diphenylcyclopropenone Alone or in Combination with Anthralin in the Treatment of Chronic Extensive Alopecia Areata: A Retrospective Case Series
    (2015) Durdu, Murat; Ozcan, Deren; Baba, Mete; Seckin, Deniz; 0000-0002-7450-6886; 0000-0003-1247-3932; 25653027; AAQ-6649-2021; H-9068-2019; HGU-2777-2022
    Background: Some patients with chronic extensive alopecia areata (AA) may be refractory to topical immunotherapy. Combination therapy is recommended for such patients. Efficacy and safety of a combination therapy with diphenylcyclopropenone (DPCP) and anthralin in chronic extensive AA is unknown. Objective: We sought to determine whether the combination therapy of DPCP and anthralin is superior to DPCP alone in chronic extensive AA. Methods: We retrospectively analyzed the efficacy, side effects, and relapse rates of DPCP (alone or with anthralin) in chronic extensive AA. Results: A total of 47 patients (22 were treated only with DPCP, and 25 with DPCP and anthralin for at least 30 weeks) were evaluated. Complete hair regrowth was observed in 36.4% and 72% of the patients who received DPCP and combination therapy, respectively (P = .01). Hair regrowth duration was shorter with combination therapy (P = .01). Regrowth rates of the eyebrows, eyelashes, and beard in patients on combination therapy were higher than those in patients on DPCP (P = .01). Side effects such as folliculitis, hyperpigmentation, and staining of skin, hair, and clothes were more common in combination therapy group. Limitations: The retrospective design and small number of patients are limitations. Conclusion: Combination therapy with DPCP and anthralin is superior to DPCP alone in chronic extensive AA.
  • No Thumbnail Available
    Item
    Smoking and Lower Urinary Tract Symptoms
    (2015) Bolat, Mustafa Suat; Akdeniz, Ekrem; Ozkaya, Sevket; Batur, Ali Furkan; Kutman, Kerem Gencer; Goren, Resit; Erdemir, Fikret; Ece, Ferah; 0000-0002-2001-1386; 26706744; Y-6143-2019
    Purpose: Pharmacologic effects of nicotine are multifaceted and complicated. Despite numerous studies, the effect of smoking on lower urinary tract functions, have not been yet studied in detail. In this study, we aimed to investigate the effects of smoking addiction on lower urinary tract and sexual functions on the basis of respiratory functions. Materials and Methods: A total of 186 male patients who have been evaluated between May 2014 and January 2015 were recruited in this study. Smoking history, respiratory symptoms, respiratory function tests, uroflowmetry parameters relating to lower urinary tract symptoms (LUTS), prostate volume, post-voiding residual urine volume and sexual functions of patients have been retrospectively investigated. Results: We determined that as the mean number of cigarettes smoked daily increases, post-void residual urine volume and International Prostate Symptom Score (IPSS) also increase. Moreover in accordance with this finding, mean urinary flow rates and quality of life scores were statistically significantly decreased. In smoking addicts who have high mean package/year, post-void residual urine volume and IPSS levels were increased but proportionately maximum urinary flow rate and average urinary flow rate plus quality of life scores were found to be statistically significantly decreased. In patients with forced expiratory volume in first second:forced vital capacity (FEV1/FVC) ratio less than 80%, mean urinary flow rates were found to be statistically significantly low. Also, we determined that in smoking addicts who have high mean package/year, erectile functions were statistically significantly impaired. Conclusion: We showed negative impacts of smoking addiction on LUTS, patient's quality of life, and sexual functions.
  • No Thumbnail Available
    Item
    Efficacy of Topical 0.05% Cyclosporine Treatment in Children with Severe Vernal Keratoconjunctivitis
    (2014) Coban-Karatas, Muge; Ozkale, Yasemin; Altan-Yaycioglu, Rana; Sizmaz, Selcuk; Pelit, Aysel; Metindogan, Sevda; Canturk-Ugurbas, Silay; Aydin-Akova, Yonca; https://orcid.org/0000-0003-3009-336X; https://orcid.org/0000-0002-9139-8848; https://orcid.org/0000-0002-0662-2033; 25818961; AAL-6136-2021; AAL-4440-2020; F-2809-2015
    We aimed to determine the efficacy of topical cyclosporine in children with vernal keratoconjunctivitis refractory to topical mast cell stabilizer and antihistamine therapy. Thirty-one patients, 24 boys and 7 girls younger than 16 years of age, were included in the study. All patients were scored on a four-point scale from 0 to 3 for symptoms and signs. Each patient received topical cyclosporine 0.05% emulsion (Restasis, Allergan Inc., Irvine, CA, USA) four times daily in addition to preservative-free artificial tears and was followed for 6 months. The data was recorded before the initiation of treatment (day 0) and at the 1st, 3rd, and 6th months following treatment. After six months of treatment, severity of all symptoms and signs showed a statistically significant decrease (p<0.05). Patients did not report any serious adverse effects. Topical cyclosporine 0.05% emulsion treatment is a safe and effective treatment option for controlling the symptoms and signs of vernal keratoconjunctivitis in children.
  • Thumbnail Image
    Item
    Tubeless Percutaneous Nephrolithotomy: Spinal versus General Anesthesia
    (2014) Gonen, Murat; Basaran, Betul
    Purpose: Tubeless percutaneous neplarolithotomy (PCNL) with double-J stenting is a good option for large kidney calculi without increasing blood loss. In many centers tubeless PCNL is performed under general anesthesia. In the present study we evaluated the impact of spinal anesthesia in patients undergoing tubeless PCNL. Material and Methods: Between February 2011 and February 2012, forty six patients with kidney calculi were treated with tubeless PCNL. Of these patients 26 were treated under spinal anesthesia (group 1) and remaining 20 were treated under general anesthesia (group 2). Groups were compared according to patient demographics, stone size, access number, operative time, presence of supracostal access, analgesic requirement, length of hospital stay, and complications. Results: There were not any statistically significant differences between groups in terms of patient demographics, mean stone size, mean access number, operative time, presence of supracostal access, and length of hospital stay. However, the analgesic requirement was significantly less in group 1 (53 +/- 39 mg vs. 111 +/- 46 mg, intravenous tramadol in groups 1 and 2, respectively P < .001). Conclusion: Tubeless PCNL under spinal anesthesia is a good alternative for general anesthesia in adult patients. Spinal anesthesia decreases analgesic requirement in patients that were performed tubeless PCNL compared to general anesthesia.